Patient Handling Equipment Market to Reach $16.4 Billion by 2030, Driven by Aging Population and Rising Chronic Disease Burden

The global patient handling equipment market is projected to grow from USD 12.4 billion in 2025 to USD 16.4 billion by 2030, at a CAGR of 5.8% during the forecast period. Market growth is primarily driven by the increasing prevalence of chronic diseases such as cardiovascular conditions, strokes, and paralysis, along with a rapidly aging global population.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186358368 

As elderly individuals are more susceptible to mobility limitations and injuries, the demand for patient handling equipment—including medical beds, patient transfer devices, and mobility aids—is rising significantly. Additionally, the growing incidence of musculoskeletal injuries among healthcare workers is accelerating the adoption of safe patient handling solutions across hospitals and care facilities.

The expansion of rehabilitation centers and long-term care facilities is further contributing to market growth, as these settings increasingly rely on advanced patient handling technologies to improve patient outcomes and caregiver safety.

Patient Transfer Devices Segment to Dominate Market

By type, patient transfer devices are expected to dominate the market during the forecast period. This segment includes patient lifts, slings, air-assisted lateral transfer mattresses, and sliding sheets.

The increasing number of patients with mobility impairments, coupled with the rising burden of chronic and age-related conditions, is driving demand for these devices. Patient transfer solutions help reduce physical strain on caregivers while ensuring safe and efficient movement of patients, making them essential in modern healthcare environments.

Rehabilitation Care Segment to Witness Highest Growth

By application, the rehabilitation care segment is projected to register the highest CAGR during the forecast period. This growth is driven by the increasing establishment of rehabilitation centers, particularly in emerging economies, and the growing demand for post-operative and recovery care.

Rehabilitation plays a critical role in restoring mobility, strength, and independence for patients recovering from injuries, surgeries, or chronic conditions. The increasing use of patient handling equipment in home healthcare, hospitals, and senior care facilities is further supporting the growth of this segment.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=186358368 

Europe Leads Global Market

In 2024, Europe accounted for the largest share of the patient handling equipment market. The region’s growth is supported by a high prevalence of chronic diseases, favorable government initiatives aimed at improving healthcare infrastructure, and a rapidly growing geriatric population.

Additionally, the rising incidence of obesity and the expansion of elderly care facilities are driving demand for patient handling solutions. The presence of leading manufacturers in the region also contributes to market growth through continuous innovation and product development.

Competitive Landscape

Key players operating in the patient handling equipment market include Arjo (Sweden), Stryker Corporation (US), Baxter International, Inc. (US), Savaria Corporation (Canada), Drive DeVilbiss Healthcare (US), Etac AB (Sweden), GF Health Products, Inc. (US), V. Guldmann A/S (Denmark), and Joerns Healthcare LLC (US), among others.

These companies are focusing on product innovation, ergonomic design, and strategic partnerships to enhance patient safety and caregiver efficiency while strengthening their global market presence.

In Vitro Fertilization Market : Driven by Rising Infertility Rates and Advancements in Reproductive Technologies

The global in vitro fertilization (IVF) market is projected to grow from USD 949 million in 2024 to USD 1,650 million by 2029, at a CAGR of 11.7% during the forecast period. Market growth is primarily driven by the increasing prevalence of infertility worldwide, largely associated with delayed parenthood, lifestyle changes, and underlying medical conditions affecting reproductive health.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89198891 

The growing acceptance of assisted reproductive technologies (ART), along with advancements in IVF procedures and laboratory equipment, is further accelerating market expansion. Increasing awareness, improving success rates, and expanding access to fertility clinics are encouraging more individuals and couples to opt for IVF treatments.

IVF Equipment Segment to Register Significant Growth

By product, the IVF equipment segment is expected to witness significant growth during the forecast period. Equipment such as imaging systems, incubators, microscopes, micromanipulators, and gas analyzers play a critical role in ensuring the success and efficiency of IVF procedures.

Advanced microscopes enable precise evaluation of sperm quality, egg maturity, and embryo development, supporting clinical decision-making at every stage. Incubators provide optimal environmental conditions for embryo growth, while centrifuges are essential for sperm preparation in procedures such as intracytoplasmic sperm injection (ICSI). Specialized tools like embryo transfer catheters further enhance implantation success rates, contributing to improved treatment outcomes.

Fresh Non-Donor IVF Cycles Dominate Market

By cycle type, fresh non-donor IVF accounted for the largest share of the market in 2023. This approach remains highly preferred as it allows individuals or couples to use their own genetic material, aligning with personal, cultural, and familial preferences.

Fresh IVF cycles are often associated with higher success rates compared to frozen or donor-based procedures, while also being more cost-effective. The ability to proceed with treatment without delays related to donor selection or embryo thawing further enhances its appeal. Additionally, personalized treatment protocols tailored to individual fertility conditions contribute to its widespread adoption.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=89198891 

Asia Pacific Emerges as a High-Growth Region

The Asia Pacific region represents a significant and rapidly growing market for IVF services. Factors such as rising infertility rates, large population base, and improving healthcare infrastructure are driving growth across countries like China, India, and Southeast Asia.

Increasing disposable incomes and growing awareness of fertility treatments are enabling more patients to access IVF services. Government support for healthcare development and the expansion of modern fertility clinics are further strengthening the region’s position as a major hub for assisted reproductive technologies.

North America held the largest share of the market in 2023, supported by advanced healthcare systems, high adoption of fertility treatments, and the presence of leading IVF service providers.

Competitive Landscape

Key players in the IVF market include CooperSurgical Inc. (US), Cook Group (US), Vitrolife (Sweden), Hamilton Thorne Ltd. (US), and FUJIFILM Irvine Scientific (Japan), among others.

These companies are focusing on technological innovation, product development, and strategic collaborations to enhance treatment success rates and expand their global presence in the fertility care market.

Refurbished Medical Equipment Market to Reach $24.41 Billion by 2029, Driven by Cost Pressures and Sustainable Healthcare Initiatives

The global refurbished medical equipment market is projected to grow from USD 16.93 billion in 2024 to USD 24.41 billion by 2029, at a CAGR of 7.6% during the forecast period. The market is witnessing strong growth due to rising healthcare costs worldwide, increasing demand for affordable medical technologies, and growing awareness around sustainability and circular economy practices.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=770 

The availability of high-quality pre-owned medical devices, coupled with rapid technological advancements and frequent equipment upgrades, is encouraging healthcare providers to adopt refurbished alternatives. Additionally, government investments in healthcare infrastructure and laboratory development are further supporting market expansion.

Refurbishment processes are also evolving with the integration of advanced technologies such as artificial intelligence (AI), enabling improved defect detection, quality assurance, and predictive maintenance. These advancements enhance reliability while reducing operational and after-sales service costs, making refurbished equipment a viable and cost-effective solution for healthcare providers.

Medical Imaging Equipment Segment Dominates Market

By product, refurbished medical imaging equipment accounted for the largest share of the market in 2023. Imaging systems such as MRI and CT scanners offer advanced diagnostic capabilities at significantly lower costs compared to new equipment, making them highly attractive to hospitals and diagnostic centers.

The increasing demand for diagnostic imaging, particularly in emerging economies, is driving adoption. Smaller healthcare facilities with budget constraints are increasingly opting for refurbished imaging systems to expand service offerings while maintaining affordability. Continuous improvements in refurbishment standards and regulatory compliance are also strengthening customer confidence in these systems.

Diagnostic Applications Lead Market Growth

By application, diagnostic applications accounted for the largest market share in 2023. The rising prevalence of chronic diseases and aging populations globally are driving the need for cost-effective diagnostic solutions.

Refurbished equipment provides a reliable and economical alternative for expanding diagnostic capabilities, particularly in resource-constrained settings. Enhanced refurbishment processes ensure quality and performance, increasing trust among healthcare providers while supporting sustainability by reducing electronic waste.

Hospitals Remain the Largest End Users

Hospitals accounted for the largest share of the refurbished medical equipment market in 2023. Budget constraints and the need for cost optimization are key factors driving adoption in this segment.

Refurbished equipment enables hospitals and surgical centers to access advanced technologies quickly and affordably, helping them meet growing patient demands without the high capital expenditure associated with new equipment. The steady availability of pre-owned devices also ensures a continuous supply to meet operational needs.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=770 

North America Leads Global Market

North America accounted for the largest share of the refurbished medical equipment market in 2023. High healthcare costs and the presence of a well-established regulatory framework are key factors driving market growth in the region.

Regulatory oversight by agencies such as the FDA ensures that refurbished equipment meets stringent safety and quality standards, boosting buyer confidence. Additionally, the growing presence of private healthcare providers and small to mid-sized facilities is increasing demand for cost-effective medical equipment solutions.

Competitive Landscape

Key players in the refurbished medical equipment market include GE Healthcare (US), Philips Healthcare (Netherlands), Siemens Healthineers (Germany), Block Imaging International, Inc. (US), Soma Technology, Inc. (US), Avante Health Solutions (US), Canon Medical Systems Corporation (Japan), Mindray Medical International (China), Drägerwerk AG & Co. KGaA (Germany), Stryker (US), Nihon Kohden Corporation (Japan), and Medline Industries (US), among others.

These companies are focusing on expanding refurbishment capabilities, enhancing product quality, and leveraging advanced technologies to strengthen their market presence.

Biochips Market : Driven by Advances in Genomics, Microfluidics, and Precision Diagnostics

The global biochips market is projected to grow from USD 14.01 billion in 2025 to USD 21.36 billion by 2030, at a CAGR of 8.8% during the forecast period. Market growth is fueled by increasing demand for faster, more accurate, and cost-effective diagnostic and research tools across genomics, proteomics, and drug discovery applications.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=54 

The adoption of biochips is expanding rapidly among research institutions, pharmaceutical companies, and clinical laboratories seeking to improve precision, throughput, and data quality. Technological advancements such as AI integration, automation, and miniaturized microfluidic platforms are transforming workflows by enabling real-time analysis and decentralized testing. Additionally, the growing use of eco-friendly, disposable biochips and connected data systems is enhancing efficiency and sustainability across the ecosystem.

DNA Chips Segment Dominates Market

By type, the DNA chips segment accounted for the largest share of the biochips market in 2024. This dominance is attributed to their critical role in genomics research, diagnostics, and personalized medicine.

DNA chips enable high-throughput analysis of gene expression, mutations, and genetic variations, making them essential tools for disease detection, drug development, and genetic testing. Their widespread adoption in clinical diagnostics and continuous advancements in microarray technology further strengthen their position as a cost-effective and scalable solution for large-scale genetic analysis.

Microfluidics Segment to Witness Highest Growth

By fabrication technology, the microfluidics segment is expected to register the highest CAGR during the forecast period. Microfluidic biochips enable precise handling of small fluid volumes, offering rapid, portable, and cost-efficient diagnostic solutions.

By integrating multiple laboratory functions onto a single chip, these systems reduce reagent consumption, accelerate testing, and expand access to point-of-care and field diagnostics. Ongoing advancements in microfabrication technologies are improving reliability and scalability, driving adoption across personalized medicine, environmental monitoring, and infectious disease detection.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=54 

North America Leads Global Market

North America accounted for the largest share of the biochips market in 2024, supported by its advanced biotechnology and healthcare infrastructure, strong R&D investments, and favorable regulatory environment.

The presence of leading biochip manufacturers, along with well-established academic and research institutions, continues to drive innovation and adoption. Increasing demand for precision medicine, personalized diagnostics, and point-of-care testing further contributes to market growth in the region.

Competitive Landscape

Key players in the biochips market include Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Abbott (US), Standard BioTools Inc. (US), 10x Genomics (US), and Cepheid (US).

These companies are focusing on technological innovation, strategic collaborations, and expanding product portfolios to strengthen their market presence and address the growing demand for advanced biochip solutions.

Body Fluid Analysis Market to Reach $3.65 Billion by 2031, Driven by Rising Disease Burden and Advances in Diagnostic Technologies

The global body fluid analysis market is projected to grow from USD 2.62 billion in 2026 to USD 3.65 billion by 2031, at a CAGR of 6.9% during the forecast period. Market growth is primarily driven by the increasing global incidence of infectious, neurological, and oncological diseases, which is creating sustained demand for advanced diagnostic solutions.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51260937 

In addition, growing requirements for forensic investigations, expanding research activities, and increasing access to specialized diagnostic infrastructure in emerging economies are further accelerating market expansion. The growing pipeline of therapies for neurodegenerative and cancer-related conditions is also encouraging the adoption of automated, high-throughput body fluid analysis systems.

Consumables Segment Dominates Market Share

By product, the consumables segment accounted for the largest share of the body fluid analysis market in 2025. This segment includes reagent kits, assay panels, stains, and other materials used in testing cerebrospinal, serous, synovial, and reproductive fluids.

The dominance of consumables is attributed to their recurring usage across diagnostic workflows, as each test requires fresh reagents. Increasing testing volumes and the transition from manual methods to multi-parameter immunoassay and flow cytometry panels are further driving demand for consumables.

Immunoassay Segment to Witness Highest Growth

By technology, the immunoassay segment is projected to register the highest CAGR during the forecast period. The growing adoption of biomarker-based testing for neurological disorders, infectious diseases, and inflammatory conditions is a key factor supporting this growth.

Automated immunoassay platforms are increasingly being used for cerebrospinal fluid (CSF) biomarker analysis due to their accuracy, scalability, and high throughput. Rising regulatory approvals and the shift toward standardized and precision diagnostics are also contributing to the rapid expansion of this segment.

Speak To Analyst :- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51260937 

Asia Pacific Emerges as Fastest-Growing Regional Market

The Asia Pacific region is expected to register the highest growth rate in the body fluid analysis market during the forecast period. Countries such as China, Japan, and India are leading this growth due to increasing healthcare investments and expanding diagnostic infrastructure.

Japan’s aging population is driving demand for advanced diagnostic testing, while China’s healthcare modernization initiatives are enhancing laboratory capacity. In India, the rapid expansion of tertiary-care hospitals and diagnostic networks is accelerating the adoption of automated body fluid analysis systems.

North America, however, accounted for the largest regional share in 2025, supported by well-established clinical laboratory infrastructure, favorable reimbursement policies, and the strong presence of leading diagnostic companies.

Competitive Landscape

Key players in the body fluid analysis market include Sysmex Corporation (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), bioMérieux SA (France), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), and Becton, Dickinson and Company (US).

These companies are focusing on product innovation, automation, and strategic collaborations to strengthen their market position and meet the growing demand for advanced diagnostic solutions.

Molecular Cytogenetics Market to Reach $1.43 Billion by 2030

The global molecular cytogenetics market is projected to grow from USD 1.02 billion in 2025 to USD 1.43 billion by 2030, at a CAGR of 7.1% during the forecast period. Market growth is primarily driven by the increasing incidence of cancer and genetic disorders, along with a growing emphasis on targeted therapies and personalized medicine.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224 

Advancements in genetic testing technologies and the expanding application of molecular cytogenetics in clinical diagnostics are strengthening its role in modern healthcare. Additionally, the aging global population and the rising prevalence of chronic diseases are further accelerating demand for accurate and reliable genomic analysis solutions.

Kits & Reagents Segment to Witness Highest Growth

By product & service, the kits & reagents segment is expected to register the highest growth rate during the forecast period. The increasing demand for standardized, ready-to-use solutions in research and clinical settings is a key factor driving this growth.

Kits and reagents streamline laboratory workflows by reducing the need for complex preparation and validation processes. Their ability to deliver high accuracy, speed, and reproducibility makes them essential tools for detecting cancer and genetic abnormalities. Continuous product innovation and the availability of specialized probes and reagents are further supporting segment expansion.

Comparative Genomic Hybridization Segment Leads Market

By technique, the comparative genomic hybridization (CGH) segment accounted for the largest share of the market and is expected to maintain its leadership throughout the forecast period. CGH is widely used for detecting chromosomal abnormalities associated with developmental disorders, congenital anomalies, and cancer.

The technology enables direct analysis of copy number variations without the need for cell culturing, resulting in faster and more reliable outcomes compared to traditional cytogenetic methods. The evolution of array-based CGH has further enhanced resolution and throughput, enabling comprehensive genomic analysis and supporting its growing adoption in oncology and genetic diagnostics.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=148469224 

Asia Pacific Emerges as Fastest-Growing Region

The Asia Pacific region is projected to register the highest CAGR in the molecular cytogenetics market. Growth in the region is driven by rising cancer incidence, increasing prevalence of genetic disorders, and ongoing improvements in healthcare infrastructure.

Government initiatives, expanding healthcare access, and growing investments in research and diagnostics are encouraging adoption of advanced cytogenetic technologies. Additionally, both global and regional players are strengthening their presence through strategic collaborations and market expansion initiatives.

Competitive Landscape

Key players in the molecular cytogenetics market include Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), Abbott (US), Agilent Technologies, Inc. (US), PacBio (US), Bio-Rad Laboratories, Inc. (US), and Bio-Techne (US).

These companies are focusing on product innovation, strategic partnerships, and expanding their global footprint to capitalize on emerging opportunities in genetic testing and precision medicine.

Immunotherapy Drugs Market : Fueled by Advances in Targeted Therapies and Rising Cancer Prevalence

The global Immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, at a robust CAGR of 15.3% during the forecast period. Market growth is driven by advancements in antibody engineering technologies, increasing demand for targeted therapies in oncology, and the growing adoption of personalized medicine.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137717755 

Immunotherapy is transforming modern healthcare by enabling the immune system to better recognize and combat diseases such as cancer and autoimmune disorders. However, factors such as stringent regulatory approval processes and the high cost of monoclonal antibody therapies may restrain market growth to some extent.

Antibody Drugs Segment Holds Largest Market Share

By type, antibody drugs accounted for the largest share of the immunotherapy drugs market. This dominance is attributed to rising cancer incidence, increased adoption of biologics, growing R&D investments, and supportive government initiatives.

The continued development of monoclonal antibodies and next-generation biologics is enhancing treatment outcomes and expanding the scope of immunotherapy across multiple therapeutic areas.

Cancer Application Segment Leads Market Demand

By application, the cancer segment is expected to dominate the market throughout the forecast period. The high global burden of cancer, coupled with increased adoption of immunotherapy-based treatments, continues to drive demand.

Pharmaceutical companies are heavily investing in clinical research, strategic collaborations, and the development of innovative therapies to improve patient outcomes. These efforts are accelerating the use of immunotherapy in oncology, offering more effective and personalized treatment options.

Intravenous Route of Administration Shows Strong Growth

By route of administration, the intravenous segment accounted for the largest market share and is projected to grow at the highest CAGR. This is due to its ability to deliver drugs directly into the bloodstream, ensuring rapid and consistent therapeutic effects.

Intravenous administration remains the preferred route for treating complex conditions such as cancer and autoimmune diseases, supporting its continued market dominance.

Hospitals Segment Drives End User Demand

By end user, hospitals generated the highest revenue in the immunotherapy drugs market. Hospitals play a critical role in administering advanced therapies, supported by specialized infrastructure and clinical expertise.

Their focus on delivering high-quality patient care, along with access to innovative treatment options and clinical trials, continues to drive demand for immunotherapy drugs.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=137717755 

North America Leads Global Market

North America is expected to dominate the global immunotherapy drugs market, driven by a strong biopharmaceutical industry, increasing cancer prevalence, and rising adoption of advanced therapies.

The region benefits from extensive research activities, a growing number of clinical trials, and continuous innovation in immunotherapy. Favorable regulatory frameworks and increased healthcare spending further support market growth.

Competitive Landscape

The immunotherapy drugs market is highly competitive, with leading players including Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), and F. Hoffmann-La Roche Ltd. (Switzerland).

Other prominent companies operating in the market include Pfizer Inc. (US), AstraZeneca (UK), Novartis AG (Switzerland), Amgen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd (Israel), GSK plc (UK), and AbbVie Inc. (US).

These organizations are focusing on innovation, strategic partnerships, and expanding their immunotherapy pipelines to strengthen their market positions and meet growing global demand.

AI in Medical Imaging Market to Reach $4.54 Billion by 2029, Driven by Rapid Adoption of AI-Powered Diagnostic Solutions

The global artificial intelligence (AI) in medical imaging market is projected to grow from USD 1.65 billion in 2024 to USD 4.54 billion by 2029, at a robust CAGR of 22.4% during the forecast period. This strong growth is fueled by increasing investments in AI-driven healthcare startups, rising cross-industry collaborations, and the growing demand for improved diagnostic accuracy and operational efficiency in healthcare systems.

Browse 523 market data Tables and 59 Figures spread through 430 Pages and in-depth TOC on "Artificial Intelligence (AI) in Medical Imaging Market".

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21977207 

AI technologies are transforming medical imaging by enhancing image interpretation, reducing diagnostic errors, and streamlining clinical workflows. However, challenges such as a shortage of skilled AI professionals and evolving regulatory frameworks may impact the pace of adoption across clinical settings.

Software Segment to Lead Market Growth

By component, the software segment is expected to dominate the AI in medical imaging market and register the highest CAGR during the forecast period. AI-powered software solutions are increasingly being adopted to address workforce shortages and rising imaging volumes.

These solutions enable healthcare providers to optimize workflows, improve resource utilization, and achieve higher diagnostic precision, providing a significant competitive advantage in clinical environments.

Radiology Segment Drives Application Demand

By application, the radiology segment is projected to hold the largest share of the market, supported by its central role in diagnostic imaging. With billions of imaging procedures conducted annually, radiology represents a key area for AI integration.

AI applications in radiology enhance accuracy, reduce diagnostic errors, and automate tasks such as lesion detection and image analysis. Meanwhile, the oncology segment is expected to witness the highest growth rate, driven by increasing demand for early cancer detection, personalized treatment planning, and precise diagnostics.

Hospitals Segment Dominates End User Market

By end user, hospitals are expected to account for the largest share of the AI in medical imaging market. The growing adoption of advanced imaging technologies and minimally invasive procedures is driving hospitals to integrate AI-powered solutions into their workflows.

AI tools support faster clinical decision-making, improve diagnostic accuracy, and reduce the burden on healthcare professionals, ultimately enhancing patient care and operational efficiency.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=21977207 

North America Leads Global Market; Asia Pacific Shows Highest Growth

North America is expected to hold the largest market share, driven by advanced healthcare infrastructure, early adoption of AI technologies, and strong investments in digital health innovation.

In contrast, the Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as increasing cancer prevalence, rising healthcare expenditure, and expanding presence of global market players are driving adoption in the region. Growing demand for early diagnosis and personalized treatment is further accelerating market growth.

Competitive Landscape

Key players in the AI in medical imaging market include Siemens Healthineers (Germany), GE Healthcare (US), Philips (Netherlands), NVIDIA Corporation (US), Aidoc (US), Lunit, Inc. (South Korea), Qure.ai (India), Viz.ai, Inc. (US), Zebra Medical Vision (Israel), Arterys (US), Therapixel (France), Enlitic, Inc. (US), Brainomix (UK), and Microsoft (US).

These companies are focusing on AI innovation, strategic partnerships, and product development to strengthen their market positions and address the evolving needs of healthcare providers.

Molecular Diagnostics Market : Driven by Advancements in Early Disease Detection and Personalized Medicine

The global molecular diagnostics market is estimated at USD 19.48 billion in 2025 and is projected to reach USD 30.74 billion by 2030, growing at a CAGR of 9.6% during the forecast period. Market expansion is driven by increasing investments in research and development, rising awareness of early disease detection, and the growing importance of personalized medicine.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=833 

Molecular diagnostics technologies offer rapid, accurate, and highly sensitive detection of diseases, enabling healthcare providers to make informed treatment decisions. As healthcare infrastructure continues to improve in emerging markets, the adoption of molecular testing is expanding across clinical and research settings.

Laboratory Testing Segment Maintains Market Leadership

By test type, laboratory-based tests accounted for the largest share of the molecular diagnostics market in 2024. This dominance is attributed to the widespread use of centralized laboratories equipped with advanced, high-throughput platforms capable of processing large volumes of samples.

Lab-based testing provides superior accuracy, sensitivity, and a broad range of assays, making it essential for complex diagnostic applications such as oncology, genetic screening, and infectious disease detection. Continued advancements in automation and multiplex technologies are further enhancing laboratory efficiency and throughput.

Blood-Based Samples Segment Expected to Grow Rapidly

By sample type, the blood, serum, and plasma segment is projected to be the fastest-growing during the forecast period. These sample types are widely used due to their reliability, ease of collection, and compatibility with various molecular diagnostic platforms.

The growth of liquid biopsy technologies and non-invasive testing methods is further accelerating demand for blood-based diagnostics. As healthcare providers increasingly prioritize minimally invasive procedures, this segment is expected to witness sustained expansion.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=833 

North America Leads Global Market

North America represents the largest regional market for molecular diagnostics, supported by a strong healthcare infrastructure and high adoption of advanced diagnostic technologies.

The region faces a significant burden of infectious diseases, cancer, and genetic disorders, which drives demand for accurate and timely diagnostics. Favorable regulatory frameworks, consistent R&D investments, and well-established reimbursement systems further support market growth. Additionally, the presence of leading diagnostic companies and advanced laboratory networks enables widespread adoption of molecular testing across clinical settings.

Competitive Landscape

Key players operating in the molecular diagnostics market include Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Illumina, Inc. (US), Abbott (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), and DiaSorin S.p.A. (Italy), among others.

These companies are focusing on expanding their product portfolios, enhancing automation capabilities, and forming strategic collaborations to strengthen their market presence and meet the growing demand for advanced molecular diagnostic solutions.

Immunoassay Market : Driven by Rising Chronic Disease Burden and Expanding Diagnostic Demand

The global Immunoassay market is projected to grow from USD 35.5 billion in 2025 to USD 47.7 billion by 2030, at a CAGR of 6.1% during the forecast period. Market growth is primarily driven by the expanding elderly population and the increasing prevalence of chronic and age-related diseases such as cancer, diabetes, and cardiovascular conditions.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436 

As healthcare systems worldwide emphasize early and accurate diagnosis, immunoassays continue to play a critical role in disease detection, monitoring, and management. Additionally, emerging markets are creating new growth opportunities, supported by increasing investments in research and development and improving healthcare infrastructure.

Reagents & Kits Segment Leads Product Market

By product, the reagents & kits segment accounted for the largest share of the immunoassay market in 2024. This dominance is largely attributed to their recurring usage in diagnostic workflows.

Unlike analyzers, which represent a one-time capital investment, reagents and kits are consumed with every test, making them essential for routine laboratory operations. Their continuous demand across a wide range of applications—including infectious diseases, endocrinology, and oncology—ensures steady revenue generation and market leadership.

ELISA Technology Maintains Market Dominance

By technology, ELISA (enzyme-linked immunosorbent assay) held the largest share of the immunoassay market in 2024. Its widespread adoption is driven by its high sensitivity, specificity, cost-effectiveness, and versatility across multiple diagnostic applications.

ELISA is particularly prominent in infectious disease testing and cancer screening, where reliable and accurate results are essential. Ongoing advancements in assay design and integration with automated systems are further enhancing its efficiency and reinforcing its position as a leading immunoassay technology.

Hospitals & Clinics Segment Leads End User Market

By end user, hospitals and clinics accounted for the largest share of the immunoassay market in 2024. These healthcare settings are central to diagnostic testing, particularly for acute and chronic conditions that require rapid and precise results.

Hospitals are equipped with advanced immunoassay platforms capable of handling high testing volumes and complex diagnostic panels. The growing adoption of automated and multiplex immunoassay systems is improving turnaround times and diagnostic accuracy, further driving demand within this segment.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=436  

North America Dominates Global Market

North America held the largest share of the immunoassay market in 2024, supported by advanced healthcare infrastructure and the strong presence of leading diagnostic companies.

The United States plays a key role in regional dominance, driven by high demand for advanced diagnostic technologies and increasing disease burden. Strategic collaborations between regulatory bodies and research organizations—such as the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration (FDA)—have contributed to the development of standardized guidelines and improved assay validation processes.

These initiatives have strengthened confidence in immunoassay performance, accelerated technology adoption, and positioned North America as a hub for innovation and regulatory leadership in the global market.

Competitive Landscape

Key players in the global immunoassay market include Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher (US), Revvity (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A. (Italy), and Bio-Rad Laboratories, Inc. (US), among others.

These companies are focusing on technological advancements, automation, and strategic collaborations to strengthen their market positions and meet the growing demand for high-performance diagnostic solutions.